This Article  • Full text  • PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on ISI (7)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Topic Collections  • Articles for Residents  • Alert me on articles by topic

T. Michael Nork, MD; Gretchen L. Poulsen; Robert W. Nickells, PhD; James N. Ver Hoeve, PhD; Nam-Chun Cho, MD; Leonard A. Levin, MD, PhD; Mark J. Lucarelli, MD

Arch Ophthalmol. 2000;118:1242-1250.

Objective  To test a hypothesis of photoreceptor involvement in retinal ganglion cell (RGC) death in chronic glaucoma.

Methods  Laser spots were applied to 6 eyes of 3 rhesus monkeys, causing focal destruction of the outer retina, including the photoreceptors. After 3 to 4 weeks, experimental glaucoma was induced in the right eyes of each monkey using argon laser trabecular destruction (ALTD). The intraocular pressures in these eyes were elevated for 3 to 7 months. As a control, 1 additional monkey underwent retinal laser photocoagulation followed by optic nerve transection instead of ALTD. Following enucleation, the retinas were embedded and sectioned for histologic evaluation.

Results  There was extensive loss of RGCs in the eyes with ALTD except over the large retinal laser spots, where there was an increased survival of RGCs. The RGC protection was not observed in the monkey that had undergone optic nerve transection.

Conclusion  Photocoagulation of the outer retina that completely destroys the photoreceptors results in survival of the overlying RGCs in experimental glaucoma in monkey eyes.

Clinical Relevance  Although this is an experimental model and not a therapeutic option, these results suggest that treatments other than lowering intraocular pressure may be potential therapies for preventing RGC death in glaucomatous eyes.

From the Department of Ophthalmology and Visual Sciences, University of Wisconsin Medical School, Madison. Dr Levin is a consultant to several pharmaceutical companies involved in neuroprotection research.

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Efficacy and Safety of Memantine Treatment for Reduction of Changes Associated with Experimental Glaucoma in Monkey, I: Functional Measures
Hare et al.
IOVS 2004;45:2625-2639.
ABSTRACT | FULL TEXT  

Retinal Oxygen: Fundamental and Clinical Aspects
Wangsa-Wirawan and Linsenmeier
Arch Ophthalmol 2003;121:547-557.
ABSTRACT | FULL TEXT  

Selective Citation of Evidence Regarding Photoreceptor Loss in Glaucoma
Quigley et al.
Arch Ophthalmol 2001;119:1390-1391.
FULL TEXT